Molecular Partners (MOLN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Molecular Partners (MOLN) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.16 of bullish evidence against -0.33 bearish.

Molecular Partners last closed at $3.92, +0.26% on the session.

Against the IVW growth benchmark the position is -0.66% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for MOLN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Molecular Partners in the 15th percentile on return on equity, where 100 is best.

Molecular Partners is classified under Health Care / Biotechnology, with a market capitalisation of $149.77M.

StockMap tracks Molecular Partners as the 243rd largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Molecular Partners ranks 195th of 344 in the group, against a group median of -0.21.